Overview

Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy for Early Gastric Cancer

Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
0
Participant gender:
All
Summary
This study aims to explore the value of indocyanine green (ICG) in laparoscopic distal gastrectomy with lymph node dissection for early gastric cancer.The patients with early gastric adenocarcinoma (cT1, N-/+, M0) will be studied.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Fujian Medical University
Criteria
Inclusion Criteria:

1. Age from 18 to 75 years

2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or
poorly differentiated) confirmed pathologically by endoscopic biopsy

3. Clinical stage tumor T1 (cT1), N0/+, M0 at preoperative evaluation according to the
American Joint Committee on Cancer (AJCC) Cancer Staging Manual Eighth Edition.
Preoperative staging was made by conducting mandatory computed tomography (CT) scans
and an optional endoscopic ultrasound

4. No distant metastasis, no direct invasion of pancreas, spleen or other organs nearby
in the preoperative examinations

5. Tumor located in the lower third of the stomach, expected to receive radical distal
gastrectomy

6. Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG)

7. American Society of Anesthesiology score (ASA) class I, II, or III

8. Written informed consent

Exclusion Criteria:

1. Women during pregnancy or breast-feeding

2. Severe mental disorder

3. History of previous upper abdominal surgery (except laparoscopic cholecystectomy)

4. History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal
dissection

5. Enlarged or bulky regional lymph node diameter over 3cm by preoperative imaging

6. History of other malignant disease within past five years

7. History of previous neoadjuvant chemotherapy or radiotherapy

8. History of unstable angina or myocardial infarction within past six months

9. History of cerebrovascular accident within past six months

10. History of continuous systematic administration of corticosteroids within one month

11. Requirement of simultaneous surgery for other disease

12. Emergency surgery due to complication (bleeding, obstruction or perforation) caused by
gastric cancer

13. Forced expiratory volume in 1 second (FEV1)<50% of predicted values

14. Rejection of laparoscopic resection

15. Preoperatively confirmed tumors invading the dentate line or duodenum

16. History of allergy to iodine agents

17. Tumor located in the upper third of the stomach, expected to receive radical total
gastrectomy